License Agreements - MorphoSys (Details) $ in Thousands, shares in Millions		1 Months Ended		12 Months Ended
	Feb. 05, 2024	May 31, 2024 USD ($) shares	Feb. 05, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
License agreements
(Profit) and loss sharing under collaboration agreements				$ (1,025)	$ 2,045	$ 7,973
Research and development				2,606,848	1,627,594	1,585,936
MorphoSys AG
License agreements
Shares divested (in shares) | shares		3.6
Proceeds from sale of equity securities, FV-NI		$ 66,600
Equity securities, FV-NI					35,900
Realized and unrealized gain (loss) on equity investments				$ 30,700	22,900	(21,200)
MorphoSys AG
License agreements
Profit (loss) sharing ratio				50.00%
Research and development			$ 10,700		76,100	99,700
Accrued and other liabilities					18,800
MorphoSys AG | Tafasitamab Product and Service | United States
License agreements
(Profit) and loss sharing under collaboration agreements			$ 1,000		$ 2,000	$ 8,000
MorphoSys AG | ADSs
License agreements
Conversion ratio		0.25
MorphoSys AG | MorphoSys AG
License agreements
Funding of future development costs	45.00%
MorphoSys AG | Incyte
License agreements
Funding of future development costs	55.00%				55.00%	55.00%